PASSION: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. A randomized, placebo-controlled, double-blind, parallel group, multi-center, phase III trial
Study, to investigate, if Tadalafil, a Phosphodiesterase-5 inhibitor, is beneficial for the treatment of pulmonary hypertension due to left heart failure
Study details
Study-ID: 2017-003688-37
Study-ID: 2017-003688-37
DZL Disease Area: PH
DZL Disease Area: PH
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL Investigator Initiated Trial, DZL recruiting center
DZL Role: DZL Investigator Initiated Trial, DZL recruiting center
DZL Participating Sites: ARCN, UGMLC
DZL Participating Sites: ARCN, UGMLC
Start Date: 02.05.2018
Completion Date: 30.06.2023
Status: Closed
Status: Closed
DZL Investigator Initiated Trial, DZL recruiting center
Disease: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction, Pulmonary hypertension in combination with left heart failure
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
